Another Post-Trump Trade: Revisiting Sun Pharmaceuticals (SUNP IN) After Q2 (FY2017) Earnings
168 Views13 Nov 2016 04:17
We initiated coverage on Sun Pharmaceutical Indus (SUNP IN) with Buy rating and common stock price target of INR 855 earlier this month. Link to...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 2-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Sun Pharma Specialty Research Pipeline – A Game Changer01 Jun 2018
- 'Cures Act', Halol Plant FDA Inspection and a Russian Acquisition.05 Dec 2016
- Another Post-Trump Trade: Revisiting Sun Pharmaceuticals (SUNP IN) After Q2 (FY2017) Earnings13 Nov 2016
- Sun Pharmaceuticals: Time To Buy This World Class Pharma Company On This Pullback.02 Nov 2016
x